Administrative
行政的
基本信息
- 批准号:8405107
- 负责人:
- 金额:$ 9.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-22 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:Biological AssayBudgetsCenters for Disease Control and Prevention (U.S.)ClinicalCommunicationComplexDataDevelopmentDoseDrug KineticsEnsureEvaluationExpenditureGelGoalsGrantHIV-1HospitalsHumanHuman ResourcesIn VitroIndividualInstitutesInstructionMethodsNational Institute of Allergy and Infectious DiseaseParticipantPerceptionPerformancePessariesPharmacodynamicsPharmacologic SubstancePlayProgram EvaluationProgress ReportsReportingResearchResearch ActivityRoleScheduleScienceScientistSeminal fluidSummary ReportsSuppositoriesTechnologyTeleconferencesTenofovirTestingTimeLineU-Series Cooperative AgreementsUnited States National Institutes of HealthUniversitiesUtahVaginaWomanWritingcost effectivein vivo Modelmeetingsmembermicrobicidenew product developmentnext generationnon-nucleoside reverse transcriptase inhibitorsnonhuman primatenovelnovel strategiesproduct developmentprogramsrectalresearch and developmentsymposiumtoolvaginal fluid
项目摘要
PROJECT SUMMARY (See instructions):
The proposed Project includes a complex interplay of both microbicide product development with single agent and combination microbicide products uniquely delivered to both the vaginal and rectal compartments, as well as microbicide science advancement in which the active microbicides will be utilized as tools to better
understand microbicide dosing, pharmacokinetics and pharmacodynamics in explants, nonhuman primates and humans, and acceptability/user perception. The product development components consist of the dual acting entry and nonnucleoside reverse transcriptase inhibitor IQP-0528 (a pyrimidinedione with subnanomolar activity against clinical strains of HIV-1) used alone and in combination with tenofovir in dual
compartment (DuoGels) gels and smart suppository/pessary (Smart Suppository) delivery vehicles that will enable dosing in both vaginal and rectal compartments. We believe the potential advancements in product development (new microbicide agents, combination products, long lasting delivery technology, dual compartment delivery technology) and microbicide science (dosing estimation, pharmacokinetics,
pharmacodynamics, in vitro, ex vivo, and in vivo modeling, effects of seminal and vaginal fluids, acceptability testing methods) make this proposal both inherently novel and important to the field of microbicide science in regard to the development of the next generation of microbicide products. In whole, the Project also provides for the development of novel PK/PD assays, novel single and combination products, novel delivery strategies, and novel microbicide development advancements to better understand and prioritize the development and use of microbicide products. The Administrative Core will play a critical and essential role in ensuring the smooth integration of the various Projects and Cores included in this cooperative agreement
research program. The successful performance of this Project requires a high degree of communication and interaction between the various Projects, the Cores, and the Corporate Partner. The Administrative Core will be responsible for managing and enhancing this constructive and synergistic interplay between the participating scientific groups.
项目摘要(参见说明):
拟议的项目包括杀微生物剂产品开发与独特地输送到阴道和直肠室的单剂和组合杀微生物剂产品之间的复杂相互作用,以及杀微生物剂科学进步,其中活性杀微生物剂将被用作更好地发挥作用的工具。
了解外植体、非人灵长类动物和人类的杀菌剂剂量、药代动力学和药效学,以及可接受性/用户感知。该产品开发组件包括双重作用入口和非核苷类逆转录酶抑制剂 IQP-0528(一种对 HIV-1 临床毒株具有亚纳摩尔活性的嘧啶二酮),可单独使用或与替诺福韦联合使用。
腔室 (DuoGels) 凝胶和智能栓剂/子宫托 (智能栓剂) 输送工具,可在阴道和直肠腔室中给药。我们相信产品开发(新型杀菌剂、组合产品、长效递送技术、双隔室递送技术)和杀菌剂科学(剂量估计、药代动力学、
药效学、体外、离体和体内建模、精液和阴道液的影响、可接受性测试方法)使该提案对于杀微生物剂科学领域的下一代杀微生物剂产品的开发具有本质上的新颖性和重要意义。总体而言,该项目还提供了新型 PK/PD 测定、新型单一和组合产品、新型递送策略和新型杀菌剂开发进展的开发,以更好地了解和优先考虑杀菌剂产品的开发和使用。行政核心将在确保本合作协议中各个项目和核心的顺利整合方面发挥至关重要的作用
研究计划。该项目的成功实施需要各个项目、核心和企业合作伙伴之间的高度沟通和互动。行政核心将负责管理和加强参与科学团体之间的这种建设性和协同作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Walter Buckheit其他文献
Robert Walter Buckheit的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Walter Buckheit', 18)}}的其他基金
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
- 批准号:
8699496 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
- 批准号:
8862358 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Critical Path IND-enabling Studies, Regulatory, and Product Development
关键路径 IND 支持研究、监管和产品开发
- 批准号:
8405106 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
- 批准号:
8494567 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Determination of Dosing Concentrations of Formulated APIs using the MTSA
使用 MTSA 确定配方 API 的剂量浓度
- 批准号:
8404125 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
- 批准号:
8374028 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
- 批准号:
8699496 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
- 批准号:
9060880 - 财政年份:2012
- 资助金额:
$ 9.54万 - 项目类别:
Discovery of drugs for use in the treatment and prevention of HIV infection using
发现用于治疗和预防 HIV 感染的药物
- 批准号:
7932473 - 财政年份:2010
- 资助金额:
$ 9.54万 - 项目类别:
Discovery of drugs for use in the treatment and prevention of HIV infection using
发现用于治疗和预防 HIV 感染的药物
- 批准号:
8245298 - 财政年份:2010
- 资助金额:
$ 9.54万 - 项目类别:
相似国自然基金
基于跨尺度自纠偏数字心脏的恶性基因突变智能预算方法研究
- 批准号:62306293
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
“预算-绩效”一体化背景下互动式目标生产对财政绩效的激励机制
- 批准号:72304179
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
地方债制度改革与企业劳动力投入:基于新《预算法》的准自然实验
- 批准号:72272166
- 批准年份:2022
- 资助金额:45 万元
- 项目类别:面上项目
中国地方政府预算波动的影响因素研究:基于政治预算周期、预算制度和官员特征的视角
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
财政预算增长目标对资源配置的影响研究
- 批准号:72173108
- 批准年份:2021
- 资助金额:45 万元
- 项目类别:面上项目
相似海外基金
A novel therapeutic to ameliorate chronic pain and reduce opiate use
一种缓解慢性疼痛和减少阿片类药物使用的新型疗法
- 批准号:
10449288 - 财政年份:2019
- 资助金额:
$ 9.54万 - 项目类别:
A novel therapeutic to ameliorate chronic pain and reduce opiate use
一种缓解慢性疼痛和减少阿片类药物使用的新型疗法
- 批准号:
9889937 - 财政年份:2019
- 资助金额:
$ 9.54万 - 项目类别:
Wearable Device to Monitor Blood Alcohol Levels in Real Time
实时监测血液酒精浓度的可穿戴设备
- 批准号:
9050244 - 财政年份:2015
- 资助金额:
$ 9.54万 - 项目类别:
A Culture-Free Platform for Rapid Fungal Pathogen Identification
快速真菌病原体鉴定的无培养平台
- 批准号:
10374805 - 财政年份:2014
- 资助金额:
$ 9.54万 - 项目类别:
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin
持续开发抗蓖麻毒素重组疫苗 (RivaxTM)
- 批准号:
7494125 - 财政年份:2006
- 资助金额:
$ 9.54万 - 项目类别: